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Abstract
In this study we show that platelet activating factor (PAF) activates PI 3-kinase over a rapid time course that correlates
closely with the aggregation response. Tyrosine kinases are involved in this response, since there is increased PI 3-kinase
activity associated with tyrosine-phosphorylated proteins. PI 3-kinase inhibitors were used to probe the dependence of PAF-
induced aggregation on PI 3-kinase. Both wortmannin and LY-294002 inhibited PAF-induced aggregation that correlated
with PI 3-kinase inhibition only when using lower concentrations of PAF giving reversible aggregation (primary phase).
Similar results were obtained with human platelets using thrombin or thrombin receptor activating peptide. The same pattern
of response was observed when activation of GPIIbIIIa was assessed by flow cytometry, i.e., PI 3-kinase inhibitors blocked
integrin activation only when lower concentrations of agonist were used. We suggest that PI 3-kinase is important for
reversible (primary) aggregation of platelets in response to PAF or thrombin, perhaps by contributing to the ‘inside-out’
activation of the platelet integrin GPIIbIIIa, only when submaximal concentrations of agonists are used. The lack of effect of
PI 3-kinase inhibitors, when high concentrations of agonist are used, suggests that PI 3-kinase-independent pathways
contribute to aggregation under these conditions. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Numerous studies have examined signaling path-
ways leading to activation of platelets in response to
various agonists. Despite the fact that platelets are
cell fragments that lack a nucleus, they maintain
many of the signaling pathways seen in nucleated
growing cells. For example, it has been shown that
platelets contain a very high concentration of several
tyrosine kinases, particularly non-receptor kinases
such as src [1,2]. Furthermore, platelet agonists
such as thrombin or platelet activating factor cause
an increase in tyrosine phosphorylation that has been
shown to be important for platelet function [3^5].
However, it may be that some of the enzymes are
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activated only as remnants from platelet precursor
cells, megakaryocytes, and they may not carry out
any functional role in platelet activation.
A key signaling enzyme that is generally associated
with cell growth and survival is PI 3-kinase. PI 3-
kinase may also ful¢ll other functions not necessarily
involved in cell growth, including e¡ects on cytoskel-
eton that may be mediated via the small GTP-bind-
ing protein, rac [6^9]. PI 3-kinase has been shown to
be activated in platelets in response to thrombin
[10,11]. While the exact role of PI 3-kinase in plate-
lets is not yet known, several studies have investi-
gated its involvement in aggregation; one study sug-
gested that the activation of PI 3-kinase in platelets
stimulated with a thrombin receptor agonist peptide
(TRAP) is important only for irreversible platelet
aggregation, but not for primary aggregation [12].
In this study we show that platelet activating fac-
tor, an alkylphospholipid with potent proaggrega-
tory properties [13] as well as a stimulator of leuko-
cyte function [14], causes activation of PI 3-kinase in
rabbit platelets, following a time course that corre-
lates with aggregation. We ¢nd that inhibition of PI
3-kinase using wortmannin (WM) or LY-294002
could completely inhibit aggregation induced by
low concentrations of PAF, while irreversible aggre-
gation induced by higher concentrations of PAF was
not inhibited to the same extent. Similarly, in human
platelets, PI 3-kinase inhibitors could inhibit aggre-
gation only when suboptimal concentrations of
thrombin were used. These results support a model
in which PI 3-kinase-dependent events play an essen-
tial role in platelet aggregation when low concentra-
tions of agonists are used. At high agonist concen-
trations, there is no need for PI 3-kinase and other
signaling pathways either impinge on common down-
stream targets, or utilize parallel pathways to ful¢ll
the same functions.
2. Materials and methods
2.1. Materials
Histopaque 1077 was from Sigma Diagnostics (St.
Louis, MO). Aluminum-backed Si 60 TLC plates
were from E. Merck (Darmstadt, Germany). WM
and LY-294002 were purchased from Sigma Chem-
ical Co. and Calbiochem (La Jolla, CA), respectively.
The enhanced chemiluminescence (ECL) system was
from Amersham Life Sciences (Montreal, Canada).
[Q-32P]ATP (6000 Ci/mmol) was from Dupont-NEN
Research Products (Boston, MA). [32P]Ortho-
phosphate (carrier-free) was from ICN Pharmaceut-
icals (Costa Mesa, CA). PI was purchased from
Avanti Polar Lipids (Alabaster, AL). PI-4-P and
PI-4,5-P2 were from Boehringer Mannheim Canada
(Laval, Quebec). Anti-PI 3-kinase (p85K polyclonal)
and anti-phosphotyrosine (4G10 monoclonal) were
from Upstate Biotechnology (Lake Placid, NY).
Anti-PI 3-kinase (p110 L polyclonal) was from Santa
Cruz Biotechnology (Santa Cruz, CA). PAC-1 anti-
body was purchased from Becton^Dickinson.
2.2. Platelet isolation
Rabbit platelets were isolated essentially according
to the method of Pinckard et al. [15]. Whole blood
from New Zealand white rabbits was expressed di-
rectly into anticoagulant (25 g trisodium citrate di-
hydrate, 14 g citric acid and 20 g glucose per liter) at
a ratio of 9:1 and used immediately. Anticoagulated
blood (30 ml) was diluted with 10 ml Tyrode’s bu¡er
pH 6.5 containing 0.1 mM EGTA and centrifuged
for 12 min at 190Ug at room temperature. The
platelet-rich plasma (8 ml) was withdrawn and
underlayered with 2 ml Histopaque 1077 solution.
Platelets, which formed a band at the Histopaque/
plasma interface after centrifugation, were diluted
with Tyrode’s bu¡er+EGTA and the Histopaque
separation repeated. The platelets were then washed
three times and counted in an automated Coulter
counter. For experiments, platelets were gently re-
suspended in Tyrode’s bu¡er pH 7.2 containing
1 mM Ca2.
Human platelets were washed and isolated accord-
ing to a previously described method [16]. Apyrase,
heparin and prostaglandin I2 were included in all
steps after the initial centrifugation to inhibit prema-
ture activation.
2.3. Platelet aggregation and GPIIbIIIa activation
Platelets were resuspended to 2.5^5.0U108/ml in
Tyrode’s solution+1 mM Ca2. Aggregation was de-
termined by the turbidimetric method in an aggreg-
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ometer. The platelet suspension (0.5 ml) was trans-
ferred to a siliconized glass cuvette containing a
small magnetic stir bar. The aggregating agent was
added in a small volume (up to 50 Wl) and light
transmission at 609 nm was recorded continuously
with a potentiometric pen recorder. Test compounds
were preincubated for 10 min at 37‡C with the plate-
let suspension. When the response to TRAP was
being tested, 500 Wg/ml ¢brinogen was added.
For experiments measuring GPIIbIIIa activation,
human platelets were incubated in the presence or
absence of LY-294002, then diluted into bu¡er con-
taining a ¢nal concentration of 0.5Wg/ml PAC-1 anti-
body, along with agonists or blocking peptides or
antibody. After mixing, platelets were incubated in
the dark for 5 min and then PAC-1 binding was
analyzed by £ow cytometry.
2.4. Detection and quantitation of intracellular PIP3
and PI-3,4-P2
Platelets were labeled with 32P by resuspending in
Tyrode’s^Hepes bu¡er, pH 7.0, to 5U109 per ml and
addition of 0.75 mCi/ml H3[32P]O4 for 90 min at
37‡C. Excess label was removed by centrifugation,
platelets were washed twice at room temperature
with fresh medium, then suspended at 3U109/ml in
Tyrode’s^Hepes bu¡er+1 mM Ca2. Platelet suspen-
sions (0.5 ml) were stimulated with agonist at 37‡C in
an aggregometer and reactions terminated by adding
50 Wl concentrated HCl (1 N ¢nal) followed by chill-
ing in an ice-bath.
Total platelet phospholipids were extracted by a
modi¢cation of a previously described method [17].
Chilled platelet suspensions were transferred to 15-ml
polypropylene tubes, then vortexed for 20 s with 1.88
ml 2:1 MeOH/CHCl3 (v/v) and allowed to stand at
room temperature for 20 min. Phases were separated
by vortexing the mixture with 0.63 ml H2O then 0.63
ml CHCl3 followed by centrifugation. The lower
phase was recovered, the upper phase re-extracted
and the organic layers combined. Two washes of
the organic layer with 0.5 ml 1:0.9 MeOH/0.1 M
EDTA (v/v) were performed. The extract was trans-
ferred to glass tubes and dried under nitrogen.
For separation of PIP3, the lipid ¢lm was dissolved
in 100 Wl 95:5 CHCl3/MeOH and applied to the ori-
gin of a 20U20 cm oxalate-treated silica-gel TLC
plate. The plate was developed to the top in the
following solvent system; CHCl3/acetone/MeOH/
acetic acid/H2O (80:30:26:24:14, v/v/v/v/v) [18],
then dried and exposed to autoradiography ¢lm. Al-
ternatively, the radioactivity was quantitated using a
Molecular Dynamics Phosphorimager. The spot cor-
responding to 32P-labeled PIP3 in stimulated platelets
was located by co-migration with authentic standard
produced by in-vitro phosphorylation of PI-4,5-P2 by
PI 3-kinase. The PIP3 spots were excised from the
TLC plate and quanti¢ed by scintillation counting.
Values were routinely normalized to total 32P dpm in
the extract.
PI-3,4-P2 was measured by de-acylation of the
PIP2 zone (PI-3,4-P2 and PI-4,5-P2) on the TLC
plate, followed by HPLC separation of the glycero-
phosphoinositides, as described previously [17]. For
resolution of glycero-PI-3,4-P2 (gPI-3,4-P2) from
gPI-4,5-P2, a shallow gradient was employed. The
injection was followed by a 10-min H2O wash then
a 60-min linear gradient to 0.25 M ammonium phos-
phate (pH 3.8), followed by a 50-min linear gradient
to 1.0 M ammonium phosphate (pH 3.8). Under
these conditions gPI-3,4-P2 and gPI-4,5-P2 eluted at
45.5 min and 48 min, respectively. 32P-gPI-4,5-P2 and
32P- gPI-3,4-P2 were identi¢ed by co-elution with de-
acylated lipid standards.
2.5. In vitro determination of phosphatidylinositol
3-kinase activity
Platelets were solubilized and PI 3-kinase activity
was determined in immunoprecipitates essentially as
described previously [19]. Brie£y, platelets in Ty-
rode’s^Hepes bu¡er, pH 7.2, containing 1 mM
Ca2 were solubilized with an equal volume of ice-
cold 2Ulysis bu¡er (2% Triton X-100, 20 mM Tris^
HCl (pH 8), 137 mM NaCl, 20% glycerol, 4 mM
EDTA, 2 mM Na3VO4, 2 mM Na3MoO4, 2 WM
phenylmethylsulfonyl £uoride, 20 Wg/ml leupeptin,
2 Wg/ml aprotinin, 20 mM NaF, 2 WM pepstatin,
20 Wg/ml soybean trypsin inhibitor). Detergent-in-
soluble materials were removed by centrifugation
for 15 min at 14 000 rpm at 4‡C. Platelet lysates
were immunoprecipitated with a monoclonal anti-
phosphotyrosine antibody (4G10), or rabbit antisera
to the p85K or p110L subunits of PI 3-kinase, washed
twice with lysis bu¡er and three times with bu¡er
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consisting of 10 mM Tris^HCl, pH 7.4. Ten Wg so-
nicated PI was mixed with the beads and kept for
10 min on ice. The kinase reaction was initiated by
adding 40 Wl of kinase bu¡er (50 WM ATP, 30 mM
Hepes (pH 7.4), 30 mM MgCl2, 200 WM adenosine)
containing 10 WCi of [Q-32P]ATP. After 15 min at
room temperature, 0.1 ml of 1 N HCl and 0.2 ml
of chloroform/methanol (1:1, v/v) were added to stop
the reaction. The samples were vortexed then the
lower organic layer (70 Wl) transferred to new tubes
and kept at 320‡C until analysis.
32P-labeled PI-3-P was separated from residual
[Q-32P]ATP (retained at the origin) by chromatogra-
phy on oxalate-treated TLC plates using a solvent
system of chloroform/methanol/water/28% ammo-
nium hydroxide (90:70:15:5, v/v/v/v). TLC plates
were exposed to X-ray ¢lm at 380‡C then radioac-
tivity incorporated into PI-3-P (PI 3-kinase activity)
was measured by excising the spot from the plate
followed by liquid scintillation counting.
3. Results
3.1. PIP3 and PI-3,4-P2 are elevated in
PAF-stimulated platelets
Rabbit platelets were labeled for 90 min with
[32P]orthophosphate then incubated for various times
with PAF under stirring conditions in an aggregom-
eter, after which lipids were separated by TLC. The
time course of appearance of PIP3 was found to cor-
relate closely with the induction of aggregation by
PAF, with a signi¢cant elevation above basal levels
observed within 30 s and a greater than 2-fold in-
crease observed by 1 min (Fig. 1). PI-3,4-P2 levels in
the same samples were analyzed following elution of
PI-bisphosphates from the TLC plates. The separa-
tion of deacylated PI-3,4-P2 from deacylated PI-4,5-
P2 was achieved by HPLC separation of the corre-
sponding glycero-phosphoinositides (Fig. 2). From
the results of a typical experiment using the average
of duplicate samples, PI-3,4-P2 was was only slightly
elevated above baseline counts after 5 s PAF treat-
ment (210 cpm in control, 230 cpm after 5 s treat-
ment). A larger increase in PI-3,4-P2 was observed
after 1 min, with 1160 cpm in the PI-3,4-P2 peak, and
this dropped to 710 cpm by 10 min. We have also
found PIP3to be elevated in thrombin-stimulated
rabbit platelets with a time course that also closely
correlates with aggregation (data not shown). These
results suggest that the appearance of the products of
Fig. 1. PIP3 elevation correlates with aggregation in PAF-stimu-
lated rabbit platelets. 32P-Labeled platelets were stimulated for
various times with 100 nM PAF in an aggregometer then total
phospholipid extracts separated by chromatography on oxalate-
treated silica gel TLC plates. (A) Autoradiogram of TLC plate
after 2 h exposure. PIP3 in platelet samples is located by co-elu-
tion with authentic PIP3 synthesized enzymatically. (B) The
PIP3 spot was excised and 32P quantitated by scintillation
counting. PIP3 levels in PAF-stimulated samples are expressed
as percentage of PIP3 counts in unstimulated platelets (basal
PIP3 = 6000 cpm). Progress of platelet aggregation in samples
subsequently extracted for PIP3 measurements is plotted on the
same graph. Data are in triplicate from a single experiment rep-
resentative of several. The data from the 5 s time point was not
plotted as it was not signi¢cantly di¡erent from controls. The
maximum in PIP3 varied between 30 s and 1 min for di¡erent
experiments, consistent with the kinetics of aggregation.
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activated PI 3-kinase in platelets may play a role in
regulation of downstream events such as aggrega-
tion.
3.2. E¡ect of PI 3-kinase inhibitors on PI 3-kinase
activity and PAF-induced platelet aggregation
Two potent and selective inhibitors of PI 3-kinase,
WM and LY-294002, were tested on rabbit platelets
for their ability to block the PAF-induced increase in
PIP3. WM inhibited PIP3 formation with an IC50
between 10 nM and 40 nM. Similarly, LY-294002
half-maximally inhibited PIP3 at 2^5 WM (data not
shown). At concentrations of 100 nM WM or 50 WM
LY-294002, complete inhibition of PI 3-kinase activ-
ity was observed, regardless of the concentration of
agonist used. WM and LY-294002 also blocked the
thrombin-induced increase in PIP3 in rabbit platelets
with a similar potency (data not shown). The IC50s
we found are very consistent with the ability of these
two inhibitors to block PI 3-kinase activation in
platelets stimulated with other agonists and in other
cell types [12,20^23].
The ability of WM or LY-294002 to inhibit plate-
let aggregation was tested to determine whether PI 3-
kinase activity is important for PAF-induced platelet
aggregation (Fig. 3). An e¡ect of the inhibitors on
aggregation was found to be very dependent upon
the concentration of PAF used, or more precisely,
upon the activation state of the platelets. When rab-
bit platelets were stimulated with concentrations of
PAF greater than 0.1 nM, they were quite resistant
to the e¡ects of WM or LY-294002. When 1 nM
PAF was used, no inhibition of platelet aggregation
was detected at concentrations of WM up to 1 WM
(Fig. 3A), a concentration at which WM is known to
inhibit other enzymes, in addition to PI 3-kinase
[24,25]. Similarly, the highest concentration of LY-
Fig. 2. PAF treatment of rabbit platelets induces formation of
PI-3,4-P2. De-acylated PI-bisphosphates isolated after TLC pre-
puri¢cation of lipid extracts from 32P-labeled PAF-stimulated
platelets were separated by strong anion exchange HPLC.
Shown are representative tracings from four separate sample in-
jections (unstimulated (A), 5 s (B), 1 min (C) and 10 min (D)
PAF stimulation) after column fractions were counted in a scin-
tillation counter. Arrow indicates the elution position of gPI-
3,4-P2. gPI-4,5-P2 is the large peak eluting at 49 min.
6
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294002 tested, 50 WM, which is a concentration that
completely inhibits PI 3-kinase activity [26], gave
only a slight inhibition of aggregation in response
to 1 nM PAF (Fig. 3B). Below certain concentrations
of PAF (usually 0.1 nM or less, depending upon the
particular platelet preparation) platelet aggregation is
reversible and exhibits only a primary phase (data
not shown). If one examines platelets stimulated
with 0.1 nM PAF, WM was able to inhibit aggrega-
tion with an IC50 less than 100 nM, and when plate-
lets were stimulated with 0.05 nM PAF, the e¡ective
IC50 was even lower, showing that at these lower
agonist concentrations, the e¡ect of WM was ob-
served at concentrations that correlated very closely
with its inhibitory e¡ect on PI 3-kinase activity. Sim-
ilarly, LY-294002 inhibited aggregation in response
to 0.1 nM PAF or lower with an IC50 of less than 10
WM (Fig. 3B).
3.3. E¡ect of PI 3-kinase inhibitors on thrombin- or
TRAP-induced platelet aggregation
The e¡ect of PI 3-kinase inhibitors on thrombin-
induced aggregation in human platelets was also
tested and similar results were obtained (Fig. 4). In
this ¢gure, aggregometer tracings are shown to dem-
onstrate that with 1 U/ml thrombin, there is no e¡ect
of PI 3-kinase inhibitors, and no evidence of rever-
Fig. 3. Inhibition of aggregation by WM and LY-294002 de-
pends on the activation state of the platelets. Rabbit platelets
were preincubated with varying concentrations of WM (A) or
LY-294002 (B) then stimulated for 1 min with the noted con-
centrations of PAF, and aggregation recorded in an aggregome-
ter. PAF levels were chosen that induced reversible or irreversi-
ble aggregation in the absence of inhibitors and normalized to
the level of aggregation observed at 1 nM PAF as 100%. Val-
ues are mean þ standard error of triplicate determinations from
a single representative experiment which was repeated at least
three times. DMSO concentrations did not exceed 0.2%. Fig. 4. E¡ect of PI 3-kinase inhibition on thrombin-induced ag-
gregation. Human platelets were stimulated with either 0.2 or
1 U/ml thrombin in the presence or absence of LY-294002 as
indicated. A representative set of tracings is shown, but similar
results have been obtained in at least 10 independent experi-
ments. In some cases, the extent of aggregation using 0.2 U/ml
thrombin did not reach the same maximal level, depending on
the individual donor, but the e¡ect of the PI 3-kinase inhibitor
was similar.
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sible aggregation. It should be stressed that the PI 3-
kinase inhibitors, at optimal concentrations used in
these experiments, are able to completely inhibit PI
3-kinase activated in response to 1 U/ml thrombin.
When 0.2 U/ml thrombin was used, aggregation was
almost to the same extent, and irreversible aggrega-
tion was also achieved. However, preincubation with
50 WM LY-294002 almost completely inhibited ag-
gregation induced by 0.2 U/ml thrombin. Human
platelets were also stimulated with various concen-
trations of TRAP to induce aggregation (Fig. 5).
At the highest concentration of TRAP (45 WM), pre-
incubation with LY-294002 at a concentration
known to e¡ectively block PI 3-kinase activity,
caused reversible aggregation, with little e¡ect on
the initial phase of platelet aggregation, similar to
results reported by Kovacsovics et al. [12]. However,
at an intermediate concentration of TRAP, there was
a signi¢cant inhibition of the early phase of aggrega-
tion, and at the lowest concentration of TRAP, 25
WM, preincubation with LY-294002 caused complete
inhibition of platelet aggregation. It is important to
note that at the higher concentrations of thrombin or
PAF that caused irreversible aggregation, the PI 3-
kinase inhibitors did not block aggregation and did
not reverse aggregation, in contrast to the results
shown here with TRAP.
3.4. Role of PI 3-kinase in activation of GPIIbIIIa
The inside-out signaling leading to changes in the
platelet integrin GPIIbIIIa were shown to involve PI
3-kinase, as determined by £ow cytometric studies
measuring binding of the PAC-1 antibody (Fig. 6).
When human platelets were stimulated with 1 U/ml
thrombin, the PI 3-kinase inhibitor again had no
e¡ect on PAC-1 binding; however, at a lower con-
centration of thrombin (0.2 U/ml), blocking PI 3-
kinase completely inhibited activation of GPIIbIIIa.
As controls, addition of RGDS or the blocking anti-
Fig. 5. TRAP-induced aggregation inhibited by LY-294002. Hu-
man platelets were stimulated with 25 WM, 30 WM, or 45 WM
TRAP, the latter concentration giving maximal, irreversible ag-
gregation. Preincubation with 25 WM LY-294002 caused reversi-
ble aggregation in response to 45 WM TRAP, caused greater in-
hibition in platelets stimulated with 30 WM TRAP, and almost
completely inhibited aggregation induced by 25 WM TRAP.
Average aggregometer readings are indicated, taken from a rep-
resentative experiment.
Fig. 6. E¡ect of PI 3-kinase inhibition on GPIIbIIIa activation.
Human platelets were stimulated with 1 U/ml or 0.2 U/ml
thrombin (1U T or 0.2U T) in the presence or absence of LY-
294002 (LY) as indicated. Activation of GPIIbIIIa was meas-
ured using £ow cytometry to measure binding of the PAC-1
antibody. Blocking of GPIIbIIIa using 7E3 or RGDS is pre-
sented as a control to show inhibition of PAC-1 binding.
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body 7E3 were shown to inhibit binding of the PAC-
1 antibody. Other controls (data not shown) showed
that the peptide RGES, which does not bind to the
integrin receptor, had no e¡ect, and detection of
GPIIbIIIa with another antibody that binds to all
forms of the integrin showed that in all cases the
same level of GPIIbIIIa expression could be de-
tected.
3.5. E¡ect of PI 3-kinase inhibitors on secretion
The e¡ects of the PI 3-kinase inhibitors on PAF
induced platelet dense granule release were measured
by quantitating the release into the medium of
[3H]hydroxytryptamine from preloaded rabbit plate-
lets. Up to 30% of the release could be inhibited by
concentrations of WM below 100 nM, or concentra-
tions of LY-294002 below 10 WM, only when low
concentrations of PAF were used, suggesting that a
portion of the granules released depend upon PI 3-
kinase, while the majority are not a¡ected by block-
ing this activity. However, little or no inhibition of
release was observed when a higher concentration of
PAF was used. Time course studies showed that any
inhibition of secretion by PI 3-kinase inhibitors was
similar whether platelets were stimulated for 1 or 5
min with PAF, ruling out the possibility that the
inhibitors were simply delaying the onset of release.
3.6. PI 3-kinase activity associated with tyrosine-
phosphorylated proteins is increased in
PAF-activated platelets
As we and others have shown, PAF or thrombin
treatment of platelets results in an increase in tyro-
sine phosphorylation in platelets [3^5], mediated by
as yet incompletely characterized tyrosine kinases.
The mechanism of activation of PI 3-kinase in re-
sponse to PAF was investigated by assaying for PI
3-kinase activity in anti-phosphotyrosine immuno-
precipitates. Following activation by PAF, platelets
were detergent-solubilized and extracts immunopre-
cipitated using 4G10 anti-phosphotyrosine antibody.
PI 3-kinase activity was increased in the immunopre-
cipitates from PAF-activated platelets (Fig. 7). The
amount of PI 3-kinase p85K subunit was increased in
the anti-phosphotyrosine immunoprecipitates from
PAF-treated platelets, correlating with the increase
in PI 3-kinase activity, however there was no detect-
able increase in tyrosine phosphorylation of this sub-
unit (data not shown). The latter result is consistent
with the activation of PI 3-kinase in response to cy-
tokines, in which no increase in tyrosine phosphoryl-
ated p85 was detected [17]. When the PI 3-kinase
activity was quantitated and compared with platelet
aggregation there was good correlation for both time
Fig. 7. Phosphotyrosine-associated PI 3-kinase activity is tightly
linked to aggregation of PAF-stimulated rabbit platelets. Plate-
lets were stimulated with 10 nM PAF for various times, solubi-
lized in lysis bu¡er, then the supernatant remaining after centri-
fugation immunoprecipitated with monoclonal antibody to
phosphotyrosine (4G10). PI 3-kinase activity was assayed in the
immunoprecipitates using PI as a substrate. 32P-labeled PI-3-P
from TLC plates was excised and quantitated in a scintillation
counter. Plots represent time-course (A) and concentration^re-
sponse (B) curves for PI 3-kinase activity in anti-phosphotyro-
sine immunoprecipitates (b) co-plotted with aggregation (F) de-
termined in the same samples. Data are averages of duplicate
samples in a single experiment. Similar results were obtained in
three independent experiments.
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courses and concentration responses (Fig. 7A,B).
This indicates a close temporal relationship between
platelet aggregation, PI 3-kinase activation and asso-
ciation of PI 3-kinase with tyrosine-phosphorylated
proteins. As expected, thrombin also stimulates an
increase in PI 3-kinase activity associated with tyro-
sine-phosphorylated proteins in both rabbit and hu-
man platelets without any detectable increase in ty-
rosine phosphorylation of either subunit (data not
shown).
4. Discussion
The activation of platelets by agonists such as
PAF or thrombin leads to an extremely rapid series
of signal transduction events that includes activation
of tyrosine kinases, serine/threonine kinases, as well
as lipid kinase activities, all within seconds to mi-
nutes of treatment [27]. The end result of these reac-
tions is to cause platelet shape changes, secretion of
granule contents and alterations in cell surface pro-
teins, particularly the major platelet integrin, GPII-
bIIIa, (or KIIbL3) which is responsible for binding to
¢brinogen. The engagement of GPIIbIIIa by dimeric
¢brinogen and stirring leads to platelet aggregation
and is also involved in the stimulation of ‘late-phase’
tyrosine kinase activity, subsequent to agonist stim-
ulation [28]. In the past few years, some attention has
been given to the role of PI 3-kinase activation in the
events leading to platelet responses. Several studies
have suggested that blocking PI 3-kinase activation
in response to agonists such as phorbol ester, lyso-
phosphatidic acid, serotonin/epinephrine and throm-
bin-receptor directed agonist peptide (TRAP) can at
least partially block aggregation [12,23,29], although
there is still little information about how the enzyme
is activated in platelets and what speci¢c signaling
events or platelet responses are controlled in this
pathway. One study showed that a role played by
the D3 phosphoinositides (products of PI 3-kinase
activity) may be to control actin polymerization
[30]. However, this was an event that was regulated
following activation of the integrin receptor, GPII-
bIIIa, and therefore cannot explain the role of PI 3-
kinase in the inside-out signaling leading to activa-
tion of GPIIbIIIa. Recently, our group has described
integrin-independent activation of the Pyk-2 tyrosine
kinase in thrombin-treated platelets, and co-immuno-
precipitation of Pyk-2 with PI 3-kinase [43].
In this study, we investigated the activation of PI
3-kinase in response to PAF treatment of rabbit
platelets and found that this agonist is able to acti-
vate the enzyme. The most direct demonstration of
PI 3-kinase activation in cells is obtained by deter-
mination of the amount of 3-phosphorylated phos-
phoinositides. We have shown that levels of PIP3 and
PIP2 increase rapidly in response to PAF, with a time
course that paralleled the aggregation of platelets
(Fig. 1). The time-course we obtained for PAF-in-
duced induction of PIP3, reported here for the ¢rst
time in platelets, is similar to that obtained when
platelets are stimulated with thrombin [22,31,32].
However, thrombin stimulation usually results in a
greater induction of PIP3 (e.g., greater than 5-fold)
than we observe for PAF [32]. The di¡erences be-
tween PAF and thrombin with respect to PIP3 in-
duction are not unprecedented in that the TXA2
mimetic, U46619 stimulates less PIP3 than does
thrombin and with di¡erent kinetics [30]. Also, an-
other platelet agonist, lyso-phosphatidic acid, indu-
ces quite a di¡erent pattern of PIP3 formation in
platelets compared to thrombin or PAF [23]. PI-
3,4-P2 was also increased but with a slower and
more prolonged time course than PIP3 (Fig. 2), as
has been observed by others [12,31^33]. It should be
noted that we have shown that initial activation of PI
3-kinase activity by thrombin, as detected by immu-
noprecipitated enzyme activity, is not a¡ected by ad-
dition of RGDS, showing that it is an early event,
independent of platelet aggregation [43].
There was also an increase in PI 3-kinase activity
associated with tyrosine phosphorylated proteins im-
munoprecipitated with an anti-phosphotyrosine anti-
body (Fig. 7), although there was no associated in-
crease in tyrosine phosphorylation of the p85 subunit
of PI 3-kinase (data not shown). We (data not
shown) and others [17,34] have also found that
thrombin causes an increase in PI 3-kinase activity
associated with tyrosine-phosphorylated proteins. In
agreement with our ¢ndings, strong platelet agonists
generally do not induce tyrosine phosphorylation of
the p85 subunit in platelets [35,36]. The only excep-
tion noted in the literature is one examining throm-
bopoietin stimulation [37]. This implies that for other
platelet agonists, as well as for PAF, PI 3-kinase
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associates with tyrosine-phosphorylated proteins, re-
sulting in an increase in enzyme activity. Another
group has shown that in a human B lymphoblastoid
cell line, PAF stimulates an increase in PI 3-kinase
activity associated with tyrosine-phosphorylated pro-
teins, although this group did not quantitate 3-phos-
phoinositides directly [38]. Interestingly, they also de-
tected PAF-induced tyrosine phosphorylation of the
p85 subunit, suggesting that the mechanism of pro-
tein tyrosine kinase involvement in PAF-induced PI
3-kinase activation may be cell type-speci¢c.
The role of PI 3-kinase activity in signal transduc-
tion events and downstream physiological responses
can be studied by the use of selective inhibitors of
this enzyme, WM and LY-294002. These inhibitors
are structurally unrelated and inhibit PI 3-kinase by
di¡erent mechanisms. WM forms a covalent linkage
at the active site, while LY-294002 is a competitive
inhibitor. As with all inhibitors, one must be cau-
tious in claiming speci¢c actions by any one com-
pound. However, the availability of the two inhibi-
tors that act by distinct mechanisms allows for a
comparison of their actions on PI 3-kinase activity
and on downstream targets, giving increased con¢-
dence in interpretation of the results. A recent study
from our laboratory demonstrated the usefulness of
such an approach when examining activation of PI 3-
kinase and MAP kinase [39]. The in vivo IC50s we
determined for WM and LY-294002 inhibition of
PAF induced PIP3 formation (5^10 nM and 2^5
WM, respectively) agree with those found previously
for both platelets and other cells [7,26,40]. When the
e¡ect of the inhibitors was tested on platelet aggre-
gation, it was apparent that concentrations where the
inhibitors were shown to be selectively blocking PI 3-
kinase activity had little or no e¡ect on aggregation
induced by a maximal stimulus by PAF (Fig. 3) or
thrombin (Fig. 4). When lower concentrations of ag-
onists were used, particularly concentrations of the
agonist that resulted in reversible platelet aggrega-
tion, then the inhibition by WM and LY-294002
correlated more closely with their ability to inhibit
PI 3-kinase. These results suggest that PI 3-kinase
plays a role in events leading to platelet aggregation,
but it is a role that can be bypassed when higher
concentrations of agonist are used.
A recent study showed that WM and LY-294002
could inhibit platelet aggregation induced by 25 WM
TRAP with IC50s of 50 nM and 25 WM, respectively
[12], but the e¡ect was primarily an inhibition of
irreversible aggregation induced by the agonist.
These authors concluded from further experiments
that activation of PI 3-kinase is necessary for pro-
longed maintenance of the platelet glycoprotein
GPIIbIIIa in an activated state and for irreversible
aggregation, possibly through PI 3-kinase stimula-
tion downstream of ¢brinogen receptor engagement.
However, when we examined the e¡ect of PI 3-kinase
inhibitors on TRAP-induced aggregation, we found
that early stages of aggregation were also inhibited
when lower concentrations of TRAP were used. It
was clear that we could reproduce the e¡ect of LY-
294002 in causing reversible aggregation. However,
this e¡ect may be unique to the use of TRAP as an
agonist, since irreversible aggregation induced by
thrombin or PAF could not be reversed, but aggre-
gation induced by lower concentrations of thrombin,
which also gave irreversible aggregation, could be
almost completely inhibited by LY-294002 (Fig. 4).
When lower concentrations of TRAP were used, the
PI 3-kinase inhibitor was able to completely block
aggregation (Fig. 5). Therefore, from our results,
we conclude that PI 3-kinase activity plays a very
important role in the early events leading to platelet
aggregation in response to low concentrations of
platelet agonists. However, at higher agonist concen-
trations, PI 3-kinase activity can be bypassed, pre-
sumably by other signaling pathways. The later
events leading to irreversible aggregation also appear
to be partially dependent on PI 3-kinase, as in the
case of TRAP stimulation or stimulation with lower
agonist concentrations, but again this can be by-
passed by strong platelet agonists. The activation
of PI 3-kinase at low agonist concentrations appears
to lead to the activation of GPIIbIIIa, as shown by
£ow cytometry studies in which the activated form of
the receptor was detected using a speci¢c antibody
that binds to the activated GPIIbIIIa. Clearly, the
ability of higher concentrations of thrombin to acti-
vate GPIIbIIIa in the absence of PI 3-kinase activity
supports the other studies, suggesting that the higher
agonist concentrations can activate pathways that
bypass the need for PI 3-kinase.
One working hypothesis is that the activity of a
downstream enzyme regulated by PI 3-kinase is nec-
essary for platelet aggregation. A candidate for such
BBAMCR 14549 28-10-99
R.W. Lauener et al. / Biochimica et Biophysica Acta 1452 (1999) 197^208206
an enzyme might be one of the PKC family of ki-
nases that are potentially regulated by phosphoryla-
tion pathways dependent upon PI 3-kinase, as has
been shown recently [41]. For PKCN, the activation
has been shown to involve phosphorylation of the
enzyme in the activation loop by the PIP3-dependent
kinase, PDK1 [41]. Clearly, this could be happening
in platelets since we have previously demonstrated a
potential modulation of PKCN in platelets dependent
upon PI 3-kinase activation [42]. However, it is pos-
sible that the PKC enzyme(s) may be regulated by
more than one phosphorylation pathway, and thus
the need for PI 3-kinase can be bypassed by alternate
activation pathways. These alternate pathways could
activate the same downstream protein kinase inde-
pendently of PI 3-kinase, or a di¡erent protein kinase
that can ful¢ll the same function. Our results are also
consistent with the possibility that PI 3-kinase is
playing a role in maintaining the ¢brinogen receptor
in an activated state. In the case of the agonist
TRAP, there may be a greater need for PI 3-kinase
to maintain the ¢brinogen receptor in its activated
state compared to other stronger agonists, which at
higher concentrations can utilize PI 3-kinase-inde-
pendent pathways. One might even speculate that
e¡ects via the di¡erent protease activated receptors,
that are di¡erentially activated by TRAP and throm-
bin, could provide a possible explanation for the dif-
ferences. Finally, we cannot rule out the possibility
that the inhibition of PI 3-kinase can have an e¡ect
by inhibition of platelet granule release. As men-
tioned, a partial inhibition of secretion was observed
following incubation with PI 3-kinase inhibitors,
which could possibly be a¡ecting a subset of the
granules, and these could be releasing agonists
(e.g., ADP) that contribute to aggregation.
The role of the gamma isoform of PI 3-kinase
(p110Q) in platelets was not investigated in this study,
but its potential contribution to the formation of 3-
phosphorylated inositol phospholipids cannot be
overlooked. Detailed studies with this isoform will
have to await the availability of better antibodies.
However, it is clear from the PI 3-kinase inhibitor
studies that the production of PI 3-kinase products
was being completely inhibited at appropriate con-
centrations. Therefore, if p110Q was playing an im-
portant role, it too was being inhibited by the PI 3-
kinase inhibitors and therefore our arguments re-
garding the role of PI 3-kinase can be generalized
to all of the isoforms.
In conclusion, we have shown that PI 3-kinase is
activated in PAF- or thrombin-stimulated platelets
and plays an important role in the aggregation re-
sponse at lower activation states, or in response to
lower concentrations of agonist, which could still be
physiologically relevant. PI 3-kinase signaling may be
of less importance at higher activation states due to
contributions from other signaling pathways that
may impinge on a common downstream event. A
key focus of future studies will be to examine the
activity of kinases dependent upon PI 3-kinase activ-
ity, and determine how they are regulated at various
agonist concentrations, in the presence or absence of
PI 3-kinase inhibitors.
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